NewcelX Obtains Patent in Brazil for Potential Type 1 Diabetes Treatment
MT Newswires Live
Jul 15
NewcelX (NCEL) has obtained a patent from the Brazilian Patent and Trademark Office protecting the manufacturing process of its lead clinical compound, NCEL-101, the company said Wednesday.
The patent, which covers its cell selection and enrichment technology, is valid until November 2036, the company said.
NewcelX said it recently completed a type B pre-Investigation New Drug meeting with the US Food and Drug Administration, regarding the drug, which is targeted at treating type 1 diabetes in combination with Eledon's anti-CD40L monoclonal antibody.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.